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Abstract: The prevalence of sarcopenia, frailty and fractures is increasing. Prevention options are
limited, but dietary factors including vitamin E have the potential to confer some protection. This
study investigated cross-sectional associations between dietary and plasma concentrations of vitamin
E with indices of skeletal muscle mass (SMM) (n = 14,179 and 4283, respectively) and bone density
(n = 14,694 and 4457, respectively) and longitudinal fracture risk (n = 25,223 and 7291, respectively)
in European Prospective Investigation Into Cancer and Nutrition (EPIC)-Norfolk participants, aged
39–79 years at baseline. Participants completed a health and lifestyle questionnaire, a 7-day diet diary
(7dDD) and had anthropometric measurements taken. Fat-free mass (as a SMM proxy) was mea-
sured using bioimpedance and bone density was measured using calcaneal broadband ultrasound
attenuation (BUA) and incident fractures over 18.5 years of follow-up. Associations between indices
of SMM, BUA and fracture risk were investigated by quintiles of dietary vitamin E intake or plasma
concentrations. Positive trends in SMM indices and BUA were apparent across dietary quintiles for
both sexes, with interquintile differences of 0.88–1.91% (p < 0.001), and protective trends for total
and hip fracture risk. Circulating plasma α- and γ-tocopherol results matched the overall dietary
findings. Dietary vitamin E may be important for musculoskeletal health but further investigation is
required to fully understand the relationships of plasma tocopherols.
Keywords: sarcopenia; frailty; skeletal muscle; bone density status; fracture risk; vitamin E
1. Introduction
The prevalence of sarcopenia (low levels of muscle strength, muscle quantity/quality
and physical function [1]), frailty and fractures is increasing in our aging society. In the UK,
the number of older people is growing; in 2018, there were 1.6 million people aged 85
years and over; by mid 2043, this is projected to nearly double to 3 million [2]. In parallel,
the number of sarcopenic patients will dramatically increase, adding to the already con-
siderable resultant public health issues [3]. A recent prospective study by Sousa et al. [4]
found that sarcopenia was independently associated with hospitalisation costs and with
an estimated increase of 34% for patients aged ≥65 years. Approximately 520,000 fragility
fractures occurred in the UK in 2017, with fracture-related costs of GBP 4.5 billion; these
numbers are estimated to increase by 26.2% and 30.2%, respectively, by 2030 [5]. Losses in
bone density and skeletal muscle mass and strength occur gradually from the age 30 years,
with increasing rates of loss in those over the age of 60 years [6,7]. These conditions are
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currently difficult to treat and, therefore, maintaining skeletal muscle and bone health
during aging is important.
It has long been established that a close physiological relationship exists between
muscle and bone, which changes with aging, but more recently it has become apparent that
this is not solely related to mechanical function [8,9]. Factors, such as myokines, that are
secreted by muscle, including insulin-like growth factor 1 and fibroblast growth factor 2,
have paracrine and endocrine effects which can affect bone repair and metabolism [10,11].
Additionally, bone secretes factors such as osteocalcin and connexin 43, that have direct
effects on muscle [12,13]. Studies have shown that both sarcopenia and frailty are risk
factors for fractures and falls [14–18].
Known determinants of muscle and bone aging [19] include modifiable lifestyle risk
factors, such as cigarette smoking, low physical activity and poor diet [20]. Limited
research exists, mainly in older adults, which suggests that vitamin E, a lipid-soluble, anti-
oxidant vitamin, may also be protective with respect to muscle mass and frailty [21–26], as
skeletal muscle is the organ with the highest consumption of oxygen in the body. Positive
associations of vitamin E intake with bone mineral density (BMD) and fracture risk have
also been reported in both men and women [27–30]. The major forms of vitamin E in food
are the α- and γ-tocopherols, and thus these are found in greater abundance than other
tocopherols and tocotrienols in tissues. The predominant form of vitamin E in the body is
α-tocopherol, which has tended to be the focus of research, although some research has
been carried out on other tocopherols, in particular, γ-tocopherol [31,32]. A number of
mechanisms have been suggested as to how vitamin E may slow down aging of skeletal
muscle [33–35]. Reduction in oxidative stress is thought to be a mechanism by which
vitamin E homologues protect bone but it has been reported that α- and γ-tocopherol have
opposing inflammatory functions and may uncouple bone turnover, such as by increasing
bone resorption without affecting bone formation [36,37].
The current study therefore aimed to investigate the potential associations of reported
dietary vitamin E intake (α-tocopherol equivalents), as well as plasma concentrations of
both α- and γ-tocopherol and the ratio of α:γ-tocopherol, with measures of skeletal muscle
mass (SMM) and bone density status concurrently, in a large cohort general population
cohort of middle-aged and elderly men and women. Additionally, both dietary and plasma
concentrations of vitamin E were examined in relation to fracture risk during 18.5 years
of follow-up.
2. Materials and Methods
2.1. EPIC-Norfolk Study Design
The Norfolk cohort of the European Prospective Investigation Into Cancer and
Nutrition (EPIC-Norfolk) is part of the Europe-wide EPIC study, which involves over
half a million people in ten countries [38] and was initially designed to investigate diet and
the risk of developing cancer. Details of cohort recruitment, data collection and participant
characteristics have been published previously [39]. In brief, participants aged between
39 and 79 years were recruited from General Practitioners’ surgeries, based in the rural
areas of Norfolk and market towns as well as the city of Norwich, from 1993 to 1997. Since
virtually all the population of the UK are registered with a general practice through the
National Health Service, general practice age sex registers act as a population sampling
frame. This cohort at baseline was comparable to the UK national population with regard
to many characteristics, including age, sex and anthropometry measurements, but it had a
lower proportion of current smokers [40]. The study was approved by the Norfolk District
Health Authority Ethics Committee (98CN01) and all participants gave written informed
consent, according to the Declaration of Helsinki. Of the 30,445 men and women who
consented to participate in the study (39% response rate), 25,639 attended a baseline health
examination (1HE) between 1993 and 1997. Of these, 15,028 attended a second health
examination (2HE) between 1998 and 2000.
Antioxidants 2021, 10, 159 3 of 27
2.2. Measurements of Body Composition
2.2.1. Height, Weight and BMI
At both health examinations, a trained nurse measured weight (to the nearest 0.1 kg)
and height (to the nearest 0.1 cm), with participants wearing light clothing and no shoes.
Body mass index (BMI) was calculated from these measurements as weight in kilograms
divided by height squared in metres (kg/m2).
2.2.2. Indices of Fat-Free Mass (FFM)
Bioelectrical impedance analysis (BIA) was carried out at 2HE, using a standardised
protocol (Bodystat, Isle of Man, UK), suitable for use in large field-based studies and shown
to be a valid [41] and reliable [42] measure of body composition. The TANITA Body Fat
Monitor/Scale TBF-531 BIA analyser (Tanita UK Ltd., Middlesex, UK) calculated body
density (BD) from total weight (Wt) in kilograms, height (Ht) in centimeters, and impedance
(Z) in ohms, using the following standard regression formulae: BD in men = 1.100455 −
0.109766 × Wt × Z ÷ Ht2 + 0.000174 × Z; BD in women = 1.090343 − 0.108941 × Wt × Z
÷ Ht2 + 0.00013 × Z. Fat-free mass (FFM) in kilograms was then calculated: FFM = Wt −
((4.57 ÷ BD − 4.142) × Wt), which is an estimate of the total mass of nonfat compartments
of the body—i.e., metabolic tissue, water, and bone. In an effort to scale for differences in
skeletal muscle mass with increasing body weight, scaled for height, FFM standardised by
BMI (FFMBMI) was calculated as FFM divided by BMI, according to the method suggested
by Studenski [43].
2.2.3. Bone Density Assessment
Quantitative ultrasound measurements of the calcaneus (heel bone) were taken at 2HE,
using a contact ultrasound bone analyser (CUBA) device (McCue Ultrasonics) following
standard protocols. Broadband ultrasound attenuation (BUA) (dB/MHz) measurements
were taken at least in duplicate for each foot of the participant, and the mean of the left
and right foot measures was used for analysis. Each of the five CUBA devices used in the
study was calibrated daily with its physical phantom. In addition, calibration between
devices was checked monthly using a roving phantom (CV 3.5%). The CUBA method of
bone density assessment has been shown to be capable of predicting fracture risk [44,45],
and is cheaper and simpler to conduct in general practice settings compared with the
gold-standard of dual-energy X-ray absorptiometry (DEXA).
2.2.4. Fracture Incidence
Self-reported fracture was recorded using questionnaires at both 1HE and 2HE, and in-
cident fracture was ascertained using linkage to the East Norfolk Health Authority database
(ENCORE) of hospital attendances by Norfolk residents [46]. Incidence of all osteoporotic
fractures in the cohort, up to the end of March 2018, was determined by retrieving data
using each participant’s National Health Service (NHS) number and searching for events
logged using the International Classification of Diseases (ICD) 9 and 10 diagnostic codes
for osteoporotic hip, spine or wrist fractures.
2.3. Measurement of Vitamin E Intake
Dietary intakes at 1HE were assessed using 7-day diet diaries (7dDDs), which were
completed by 25,507 participants, detailing all food and drink consumed, together with
the portion sizes. Data Into Nutrients for Epidemiological Research (DINER) software was
used to enter the dietary information provided by the 7dDDs [47], which was then checked
and processed by nutritionists to obtain nutrient data using DINERMO [48]. Vitamin and
mineral supplements recorded in the 7dDD were quantified using the Vitamin and Mineral
Supplement (ViMiS) database [49].
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2.4. Blood Analysis
At 1HE, a 42 mL sample of blood was collected in citrated and plain monovettes
and stored in a refrigerator. The next day, blood samples were processed and stored at
−196 ◦C as plasma and serum. Serum cholesterol was determined for the full cohort in
a Norfolk laboratory using a RA 1000 Diagnostics (Bayer, Basingstoke, UK) instrument,
and cohort concentrations ranged from 2.10 to 12.40 mmol/L. The vitamins α- and γ-
tocopherol were analysed on a cohort subset that consisted of a series of previous case-
control studies, where cases were defined by incident cardiovascular disease or cancer
and four matched, disease-free controls. Plasma concentrations were analysed at IARC,
Lyon (France), using high-performance liquid chromatography for the vitamins. In our
analyses, concentrations for α-tocopherol ranged from 0.71 the 106.54 µmol/L and from
0.03 to 9.85 µmol/L for γ-tocopherol; we excluded one participant for whom the ratio
of α-tocopherol to γ-tocopherol was greater than 1000). Plasma α- and γ-tocopherol
concentrations were adjusted for cholesterol, as this is seen as a more reliable marker for
vitamin E nutritional status [50] since tocopherols are transported via circulation through
lipoproteins; adjusted concentrations are presented in µmol/mmol, calculated by dividing
the plasma tocopherol concentrations (µmol/L) by total cholesterol (mmol/L).
2.5. Measurement of Confounding Variables
Data collected via two self-administered health and lifestyle questionnaires (HLQ1 and
HLQ2), before the 1HE and 2HE, respectively, were used to establish classification of a num-
ber of variables. Family history of osteoporosis was categorised as yes or no; menopausal
status (women only (2HE)) was categorised as premenopausal, perimenopausal (<1 year),
perimenopausal (1–5 years) or postmenopausal; hormone replacement therapy (HRT)
status (women only (2HE)) was categorised as current, former or never users. The use
of statins and steroids at 2HE were categorised as yes or no. Smoking status (derived
from HLQ2) (never, former, current) was derived from yes and no responses to the fol-
lowing questions “Have you ever smoked as much as one cigarette a day for as long as a
year?” and “Do you smoke cigarettes now?”. Self-reported physical activity (derived from
HLQ1) was assessed using both occupational and leisure activities and individuals were
assigned to one of four categories: inactive, moderately inactive, moderately active and
active [51,52]. Occupational social class at 1HE was defined according to the Registrar Gen-
eral’s classification. Nonmanual occupations were represented by codes I, (professional)
II, (managerial and technical), and IIIa (nonmanual skilled) occupations while manual
occupations were represented by codes IIIb (manual skilled), IV (partly skilled) and V
(unskilled) occupations [53].
2.6. Statistical Analysis
All analyses were stratified by sex as significant differences in body composition,
SMM and age-related changes in bone existing [44] between men and women. p < 0.05 was
considered to be statistically significant in individual analyses. To minimise missing data
exclusions, some missing values were recoded as follows: missing menopausal status data
(2.8%) as premenopausal if age <50 years and never-user of HRT, or as postmenopausal if
age >55 years or a current or former HRT user. Participants missing data for other variables
in the multivariable model were excluded. Participants were excluded from analyses if
they had missing or extreme BIA impedance values (<300 or >1000 ohms [54]), FFM < 25,
or for participants with extremes of BMI (<14 or ≥36 kg/m2), since bioelectrical impedance
measures are considered unreliable at these levels [55].
2.7. Cross-sectional Analyses
Cross-sectional analyses were carried out using data from the 2HE, using dietary
or plasma data from the 1HE; 14,179 participants had complete data for diet and muscle
analyses, and 4283 had complete data for plasma and muscle analyses; the figures for BUA
analyses are 14,694 and 4457, respectively (Figure 1).
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Figure 1. Flowchart of participants included in the analyses.
Multivariable adjusted regression with ANCOVA was used to investigate differences
in indices of SMM and calcaneal BUA across sex-specific dietary intake quintiles of vitamin
E intake (mg α-tocopherol equivalents). Trend testing was achieved by treating the median
values for quintiles as a continuous variable [56]. Each model was adjusted for important
physiological, lifestyle, and dietary factors, known to influence risk in this population. For
SMM, these included age, smoking status, physical activity, social class, energy intake,
percentage energy from protein, corticosteroid and statin use, menopausal and HRT status
in women; for BUA, these included age, BMI, family history of osteoporosis, menopausal
and HRT status in women, corticosteroid use, smoking status, physical activity, Ca intake,
total energy intake, and Ca- and vitamin D-containing supplement use. The data were also
analysed to take the amount of vitamin E from supplements into consideration, as excluding
supplements may underestimate total nutrient intake [57]. In separate analyses, indices
of SMM and calcaneal BUA were investigated across sex-specific plasma concentration
quintiles of α-tocopherol, γ-tocopherol and the ratio of α:γ-tocopherol, with the covariates
described above, but excluding dietary intake data.
2.8. Longitudinal Analyses
Longitudinal analyses used data from the 1HE together with incident hospital-recorded
fractures for the participants (all hip, spine and wrist fracture cases up to 31 March 2018);
the mean follow-up time was 18.5 years (467,077 total person years), and was calculated
as the time between an individual’s 1HE and this cut-off date, or death if earlier. Data
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for diet and fracture analyses were available for 25,223 participants; data for plasma and
fracture analyses were available for 7291 participants (Figure 1). Prentice-weighted Cox
regression was used to investigate associations between incidence of fractures and sex-
specific quintiles of dietary vitamin E intake (mg α-tocopherol equivalents), or plasma
concentrations, using the same adjustments as for the BUA models. Missing values were
treated in the same way as in the BUA models. Total risk for hip, spine or wrist fracture
was calculated as the risk for the first occurrence of one of these fractures; this does not
consider multiple fractures, and therefore the sum of the specific-site fracture incidences
does not sum to the total.
3. Results
3.1. Characteristics of the Study Population
Selected characteristics are summarised in Table 1, stratified by dietary analysis
group and sex. Mean dietary and supplement-derived intakes of α-tocopherol equiv-
alents (mg/day) are shown for the different study groups. In the dietary model analyses,
numbers of men and women are similar for the SMM and BUA measures and intakes
of dietary and supplement α-tocopherol equivalents are also similar. Dietary intakes of
α-tocopherol equivalents are slightly lower in the fracture dietary analyses groups, as is
the percentage of participants taking vitamin E-containing supplements and the amount of
α-tocopherol equivalents obtained from these supplements. No UK Reference Nutrient
Intake value [58] has been defined for vitamin E, although safe intakes of α-tocopherol
equivalents have been set at 4 mg for men and 3 mg for women. Of the 11,427 men
in the fracture dietary analysis group, 1.7% had an intake <4 mg (n = 194); 1.0% of the
13,796 women had an intake <3 mg (n = 132). However, the European Food Safety Agency
(EFSA) Panel on Dietetic Products, Nutrition and Allergies (NDA) set Adequate Intakes
(AIs) of α-tocopherol for adults as 13 mg/day for men and 11 mg/d for women [59]; it was
felt that Average Requirements (ARs) and Population Reference Intakes (PRIs) could not be
set for α-tocopherol. Only 30.7% of the men and 25.8% of the women in the fracture cohort
met these AIs. The fracture dietary analyses groups had a higher percentage of current
smokers, manual workers and physically inactive participants.
Table 2 presents selected characteristics, stratified by plasma analysis group and sex.
Mean dietary and supplement-derived intakes of α-tocopherol equivalents (mg/day) are
shown for the different study groups, in addition to plasma tocopherol concentrations,
unadjusted and adjusted for cholesterol. In the plasma model analyses, numbers of men
and women are similar for the SMM and BUA measures and concentrations of the plasma
tocopherols and intakes of dietary and supplement α-tocopherol equivalents are also
similar. Concentrations of the cholesterol-adjusted plasma tocopherols are also similar
in the fracture plasma analysis groups, although the ratio is slightly lower in both men
and women. A plasma tocopherol concentration of at least 11.6 µmol/L, or a minimum
tocopherol:cholesterol ratio of 2.25 µmol/mmol is considered to be the lowest satisfactory
value; the dietary requirement of vitamin E is that which is necessary to keep the ratio above
this level [58], although in a recent publication by EFSA, it was considered that they were
insufficient data on markers of α-tocopherol intake/status/function (e.g., plasma/serum
α-tocopherol concentration, markers of oxidative damage) to calculate the requirement
for α-tocopherol [59]. Of the participants in the SMM plasma analysis group, only 4 men
and 8 women had values <11.6 µmol/L; one of these woman had a tocopherol:cholesterol
ratio <2.25 µmol/mmol. Eight men and 13 women had tocopherol:cholesterol ratios
<2.25 µmol/mmol. Once again, the larger fracture plasma analysis groups had a higher
percentage of current smokers, manual workers and physically inactive participants.
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Table 1. Selected characteristics of the European Prospective Investigation Into Cancer and Nutrition (EPIC)-Norfolk cohort population, stratified by sex and diet analysis group.














Age (years) 62.8 9.0 61.5 9.0 62.9 9.0 61.5 9.0 59.6 9.3 58.9 9.3
BMI (kg/m2) 26.7 3.0 26.1 3.7 26.9 3.3 26.5 4.4 26.5 3.3 26.2 4.4
Dietary α-tocopherol equivalents intake
(mg/day) 11.90 5.00 9.52 3.73 11.91 5.04 9.50 3.74 11.63 5.24 9.29 3.78
Energy intake (kcal/day) 2287 501 1736 378 2285 502 1732 380 2240 528 1695 395
Protein intake (% energy) 14.8 2.4 15.5 2.8
Calcium intake (mg/day) 942 289 785 243 919 297 767 248
Vitamin D intake (µg/day) 3.88 2.82 2.99 1.94 3.73 2.75 2.94 2.08
Vitamin E-containing supplement use, n (%) 1000 16.0 2077 26.2 1024 15.9 2153 26.1 1587 13.9 3244 23.5
Supplemental α-tocopherol equivalents
(mg/day) 37.27 91.86 35.99 77.52 37.73 93.61 35.12 75.72 35.10 85.16 35.29 78.73
Vitamin D-containing supplement use, n (%) 1612 25.0 2752 33.4 2551 22.3 4232 30.7
Supplemental vitamin D (µg/day) 4.34 2.84 4.17 2.57 4.25 2.75 4.18 2.66
Calcium-containing supplement use, n (%) 102 1.6 504 6.1 165 1.4 742 5.4
Supplemental calcium (mg/day) 200 195 347 269 196 190 342 268
FFM (kg) 61.6 5.8 40.6 4.5
FFMBMI 2.32 0.26 1.59 0.26
BUA (dB/MHz) 90.06 17.51 72.09 16.46
Total incident fractures, n (%) 877 7.7 2092 15.2
Incident hip fractures, n (%) 356 3.1 971 7.0
Incident spine fractures, n (%) 223 2.0 357 2.6
Incident wrist fractures, n (%) 155 1.4 504 3.6
Social class, n (%)
Professional 516 8.2 544 6.9 523 8.12 565 6.85 860 7.5 863 6.3
Managerial 2566 41.0 2919 36.9 2630 40.82 3016 36.55 4299 37.6 4722 34.2
Skilled nonmanual 782 12.5 1545 19.5 804 12.48 1600 19.39 1404 12.3 2684 19.4
Skilled manual 1401 22.4 1565 19.8 1440 22.35 1636 19.83 2840 24.8 2847 20.6
Semiskilled 771 12.3 937 11.8 803 12.46 1001 12.13 1501 13.1 1805 13.1
Nonskilled 145 2.3 262 3.3 153 2.37 282 3.42 334 2.9 536 3.9
Missing 85 1.4 141 1.8 90 1.4 151 1.83 189 1.6 339 2.5
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Smoking status, n (%)
Current 490 7.8 638 8.1 509 7.9 660 8.0 1391 12.2 1560 11.3
Former 3495 55.8 2547 32.2 3609 56.01 2697 32.69 6232 54.5 4446 32.2
Never 2281 36.4 4728 59.8 2325 36.09 4894 59.31 3804 33.3 7790 56.5
Physical activity, n (%)
Inactive 1712 27.3 2043 25.8 1779 27.61 2165 26.24 3516 30.8 4174 30.3
Moderately inactive 1576 25.2 2575 32.5 1615 25.07 2695 32.66 2810 24.6 4429 32.1
Moderately active 1567 25.0 1920 24.3 1601 24.85 1980 24.00 2635 23.1 3074 22.3
Active 1411 22.5 1375 17.4 1448 22.47 1411 17.10 2466 21.6 2119 15.4
Family history of osteoporosis, n (%)
No 6098 97.4 7413 93.7 6267 97.3 7731 93.7 11,121 97.3 12,988 94.1
Yes 166 2.6 500 6.3 176 2.7 520 6.3 306 2.7 808 5.9
Corticosteroid use, n (%)
Current or former (>3 months) 260 4.2 402 5.1 270 4.2 422 5.1 349 3.0 478 3.5
Never (<3 months) 6006 95.8 7511 94.9 6173 95.8 7829 94.9 11,078 97.0 13,318 96.5
Statin use, n (%)
No 5922 94.5 7623 96.3
Yes 344 5.5 290 3.7
Menopausal status, n (%)
Premenopausal 472 6.0 482 5.8 233 16.9
Perimenopausal (<1 y) 265 3.4 272 3.3 750 5.4
Perimenopausal (1–5 y) 1389 17.6 1455 17.6 2473 17.9
Postmenopausal 5787 73.1 6042 73.2 8239 59.7
HRT, n (%)
Current 1693 21.4 1757 21.3 2802 20.3
Former 1417 17.9 1482 18.0 1570 11.4
Never 4803 60.7 5012 60.7 9424 68.3
Values are mean ± SD or frequency (percentage). SMM = skeletal muscle mass; BUA = broadband ultrasound attenuation; FFM = fat-free mass; HRT = hormone replacement therapy. * SMM and BUA
group characteristics at second health examination (2HE) (time of ultrasound), unless only available at 1HE. † Fracture group characteristics at 1HE or time of consent. SMM: men = 6264 for family history
of osteoporosis.
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Table 2. Selected characteristics of the EPIC-Norfolk cohort population, stratified by sex and plasma analysis group.













Age (years) 67.0 7.5 64.5 8.5 67.0 7.5 64.5 8.5 64.39 7.87 62.02 8.72
BMI (kg/m2) 26.8 3.0 26.3 3.7 27.0 3.4 26.8 4.3 26.74 3.33 26.39 4.20
Dietary α-tocopherol equivalents
intake (mg/day) 11.35 4.70 9.30 3.56 11.38 4.72 9.28 3.59 11.02 4.76 9.12 3.69
Serum α-tocopherol (µmol/L) 26.44 7.74 28.39 8.35 26.47 7.88 28.42 8.34 26.36 7.90 28.53 8.50
Serum chol-adjusted α-tocopherol
(µmol/mmol) 4.35 1.06 4.43 1.05 4.37 1.08 4.43 1.05 4.34 1.07 4.42 1.06
Serum γ-tocopherol (µmol/L) 1.83 0.90 1.83 0.91 1.83 0.90 1.84 0.93 1.86 0.90 1.88 0.94
Serum chol-adjusted γ-tocopherol
(µmol/mmol) 0.30 0.14 0.28 0.13 0.30 0.14 0.29 0.13 0.31 0.14 0.29 0.14
Serum α-tocopherol:γ-tocopherol
ratio (chol-adjusted) 17.97 16.27 20.61 29.31 17.96 16.53 20.41 28.73 17.55 15.29 19.92 25.35
FFM (kg) 61.31 5.80 40.45 4.66
FFMBMI 2.30 0.25 1.56 0.25
BUA (dB/MHz) 89.45 17.75 69.83 16.16
Total incident fractures, n (%) 308 8.3 643 18.0
Incident hip fractures, n (%) 129 3.5 313 8.8
Incident spine fractures, n (%) 89 2.4 124 3.5
Incident wrist fractures, n (%) 40 1.1 152 4.3
Energy intake (kcal/day) 2217 488 1715 374 2218 489 1709 377 2161 502 1675 383
Calcium intake (mg/day) 924 283 780 250 900 283 764 249
Vitamin D intake (µg/day) 3.95 2.72 3.04 1.97 3.85 2.71 3.02 2.21
Vitamin E-containing supplement
use, n (%) 350 15.7 512 25.0 360 15.6 534 24.8 503 13.5 806 22.6
Supplemental α-tocopherol
equivalents (mg/day) 36.05 92.50 39.84 83.53 36.13 92.35 39.12 82.00 34.54 85.44 38.10 80.96
Vitamin D-containing supplement
use, n (%) 596 26.7 657 32.0 607 26.3 682 31.7 893 24.0 1075 30.2
Supplemental vitamin D (µg/day) 4.35 2.78 4.30 2.71 4.35 2.77 4.35 2.74 4.27 2.70 4.25 2.80
Calcium-containing supplement use,
n (%) 38 1.7 109 5.3 38 1.6 113 5.3 53 1.4 174 4.9
Supplemental calcium (mg/day) 195 193 334 250 195 193 338 248 230 219 314 249
Social class, n (%)
Professional 179 8.02 114 5.56 181 7.84 120 5.58 258 6.92 192 5.39
Managerial 905 40.55 731 35.64 934 40.47 762 35.46 1382 37.08 1195 33.53
Skilled nonmanual 293 13.13 422 20.58 302 13.08 436 20.29 475 12.74 708 19.87
Skilled manual 493 22.09 403 19.65 509 22.05 422 19.64 926 24.85 711 19.95
Semiskilled 280 12.54 262 12.77 294 12.74 280 13.03 504 13.52 502 14.09
Nonskilled 48 2.15 68 3.32 51 2.21 76 3.54 115 3.09 145 4.07
Missing 34 1.52 51 2.49 37 1.60 53 2.47 67 1.8 111 3.11
Smoking status, n (%)
Current 165 7.39 145 7.07 168 7.28 148 6.89 410 11.00 388 10.89
Former 1337 59.90 668 32.57 1394 60.40 711 33.09 2240 60.10 1171 32.86
Never 730 32.71 1238 60.36 746 32.32 1290 60.03 1077 28.90 2005 56.26
Physical activity, n (%)
Inactive 705 31.59 581 28.33 740 32.06 614 28.57 1363 36.57 1212 34.01
Moderately inactive 537 24.06 678 33.06 545 23.61 714 33.22 883 23.69 1121 31.45
Moderately active 525 23.52 485 23.65 539 23.35 502 23.36 790 21.20 769 21.58
Active 465 20.83 307 14.97 484 20.97 319 14.84 691 18.54 462 12.96
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Table 2. Cont.













Family history of osteoporosis, n (%)
No 2177 97.58 1929 94.05 2249 97.44 2025 94.23 3645 97.8 3381 94.87
Yes 54 2.42 122 5.95 59 2.56 124 5.77 82 2.2 183 5.13
Corticosteroid use, n (%)
Current or former (>3 months) 123 5.51 116 5.66 130 5.63 123 5.72 150 4.02 142 3.98
Never (<3 months) 2109 94.49 1935 94.34 2178 94.37 2026 94.28 3577 95.98 3422 96.02
Menopausal status, n (%)
Premenopausal 31 1.51 33 1.54 287 8.05
Perimenopausal (<1 y) 44 2.15 44 2.05 155 4.35
Perimenopausal (1–5 y) 268 13.07 283 13.17 534 14.98
Postmenopausal 1708 83.28 1789 83.25 2588 72.62
HRT, n (%)
Current 396 19.31 410 19.08 660 18.52
Former 348 16.97 370 17.22 390 10.94
Never 1307 63.73 1369 63.70 2514 70.54
Values are mean ± SD or frequency (percentage). SMM = skeletal muscle mass; BUA = broadband ultrasound attenuation; FFM = fat-free
mass; HRT = hormone replacement therapy. Serum BUA: Men = 2300 for vitamin E, vitamin D, calcium and energy intakes; women = 2143
for vitamin E, vitamin D, calcium and energy intakes. Serum fracture: men = 3707 for vitamin E, vitamin D, calcium and energy intakes;
women = 3551 for vitamin E, vitamin D, calcium and energy intakes. SMM: men = 2231 for family history of osteoporosis; women = 2045
for body mass index (BMI). * SMM and BUA group characteristics at 2HE (time of ultrasound), unless only available at 1HE. † Fracture
group characteristics at 1HE or time of consent.
3.2. Food Sources of α- and γ-Tocopherols
Good sources of vitamin E include plant oils—such as rapeseed, sunflower, soya,
corn and olive oil—nuts, seeds and wheatgerm. The main sources of γ-tocopherol include
oils [60] (especially soybean and corn oils, which are used extensively in processed foods),
nuts and seeds [61] (especially walnuts, pecans and pistachios, as well as sesame, flax and
pumpkin seeds), as well as spinach, carrots, avocado, dark green leafy vegetables and
wheatgerm. Figure 2 shows the main food group sources for men and women. Generally,
the main food groups contributing to vitamin E intake in men and women were similar, with
butters, spreads and margarines being the main contributors. Foods in the grains and cereal-
based products groups include both sweet and savoury biscuits, cakes, pies and quiches.
3.3. Correlations between Dietary Vitamin E Intake and Plasma Concentrations
A number of weak but significant correlations were found between the dietary intake
of α-tocopherol equivalents and plasma concentrations of α-tocopherol. Dietary intake
of α-tocopherol equivalents was significantly correlated with plasma concentration of
α-tocopherol in the SMM cohort in men (r = 0.079, p < 0.001, n = 2232), but not in women
(r = 0.038, p = 0.084, n = 2051). In the BUA cohort, significant correlations were found in
both men (r = 0.083, p < 0.001, n = 2300) and women (r = 0.044, p < 0.05, n = 2143). In the
fracture cohort, dietary intake of α-tocopherol equivalents was significantly correlated
with plasma concentration of α-tocopherol in both men (r = 0.105, p < 0.001, n = 3707) and
women (r = 0.08, p < 0.001, n = 3551).
When the plasma concentration of α-tocopherol was adjusted for total cholesterol,
the correlations with dietary intake were found to be slightly stronger. Dietary intake
of α-tocopherol equivalents was significantly correlated with plasma concentration of
α-tocopherol in the SMM cohort in both men (r = 0.136, p < 0.001, n = 2232) and women
(r = 0.1203, p < 0.001, n = 2051). In the BUA cohort, significant correlations were found
in both men (r = 0.131, p < 0.001, n = 2300) and women (r = 0.125, p < 0.001, n = 2143). In
the fracture cohort, dietary intake of α-tocopherol equivalents was significantly correlated
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with plasma concentration of α-tocopherol in both men (r = 0.1565, p < 0.001, n = 3707) and
women (r = 0.153, p < 0.001, n = 3551).
Figure 2. Percentage composition of food groups for vitamin E intake of men and women in the EPIC-Norfolk cohort.
“Butters, spreads and margarines” include reduced fat types. “Grains and cereal-based products” include rice and rice-
based dishes, pasta, sweet and savoury flans, pies and quiches, biscuits, cakes, breads and bread rolls. “Vegetables and
vegetable-based dishes” include raw and cooked vegetables, vegetable dishes and mixed salads. “Breakfast cereals” include
porridge and muesli. “Potatoes, including products and dishes” include potatoes, potato products, dishes and salads. “Fish,
including shellfish, products and dishes” includes shellfish and fish-based dishes. “Cooking fats and oils” include hard
margarines, animal fats, vegetable fats and ghee. “Fruit” includes fresh, cooked and canned fruit. “Potato and cereal-based
savoury snacks” include crisps and other potato-based snacks and bread/pastry type snacks. “Meat, including products and
dishes” include unprocessed white and red meats (and products and dishes), processed meat products and offal, including
products and dishes. “Nuts and seeds” include nuts, seeds and nut butters. “Dairy” includes milk, cheese, yoghurts and
dairy-based desserts. “Other” includes sugar, herbs and spices and dietetic products. “Soups” include homemade, canned
and reconstituted dried soups. “Sauces” include sweet and savoury sauces, gravies, salad dressings, pickles, chutneys and
stuffing. “Eggs” include eggs and sweet and savoury egg dishes. “Beverages” include alcoholic and nonalcoholic drinks,
such as tea, coffee, water, soft drinks, fruit juice and squashes. “Legumes” include beans, pulses and lentils, dried, cooked
and canned, and legume-based salads.
3.4. Associations between Dietary Vitamin E Intakes and Indices of SMM
Significant positive associations were found between sex-specific quintiles of dietary
vitamin E and FFM and FFMBMI (p-trend < 0.001 in both men and women), after adjust-
ments for covariates (Table 3), with significant interquintile differences (Q5 versus Q1) in
FFM of +1.0% (p < 0.001) in both men, and women, and in FFMBMI of +1.7% (p < 0.001) in
men and +1.9% (p < 0.001) in women. The addition of the amount of vitamin E derived
from supplements to the fully adjusted models did not alter the associations.
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Table 3. Associations between quintiles of dietary vitamin E and skeletal muscle mass in men and women aged 42–82 years.
Men (n = 6266) Dietary α-TocopherolEquivalents Intake (mg/day) FFM FFMBMI
Quintile Mean ± SD Median Unadjusted Adjusted Unadjusted Adjusted
1 (n = 1254) 6.45 ± 1.19 6.72 60.56 ± 0.17 61.23 ± 0.16 2.25 ± 0.01 2.30 ± 0.01
2 (n = 1253) 9.00 ± 0.54 9.03 61.29 ± 0.16 ** 61.45 ± 0.14 2.31 ± 0.01 *** 2.32 ± 0.01 *
3 (n = 1253) 10.93 ± 0.62 10.88 61.64 ± 0.17 *** 61.67 ± 0.14 * 2.32 ± 0.01 *** 2.32 ± 0.01 *
4 (n = 1253) 13.45 ± 0.90 13.36 62.20 ± 0.16 *** 61.86 ± 0.15 ** 2.36 ± 0.01 *** 2.34 ± 0.01 **
5 (n = 1253) 19.67 ± 4.54 18.30 62.40 ± 0.16 *** 61.86 ± 0.15 ** 2.38 ± 0.01 *** 2.34 ± 0.01 **
Q5–Q1 diff 1 1.84 0.63 0.13 0.04
% diff 2 3.04 1.03 5.78 1.74
p trend <0.001 <0.001 <0.001 <0.001
Women (n = 7913)
Quintile Mean ± SD Median Unadjusted Adjusted Unadjusted Adjusted
1 (n = 1583) 5.36 ± 0.99 5.58 39.95 ± 0.12 40.45 ± 0.12 1.52 ± 0.01 1.57 ± 0.01
2 (n = 1583) 7.41 ± 0.44 7.42 40.30 ± 0.11 * 40.47 ± 0.11 1.56 ± 0.01 *** 1.57 ± 0.01
3 (n = 1582) 8.94 ± 0.45 8.96 40.64 ± 0.11 *** 40.65 ± 0.11 1.59 ± 0.01 *** 1.59 ± 0.01
4 (n = 1583) 10.74 ± 0.64 10.70 41.04 ± 0.11 *** 40.80 ± 0.11 * 1.62 ± 0.01 *** 1.60 ± 0.01 **
5 (n = 1582) 15.14 ± 3.55 14.13 41.31 ± 0.11 *** 40.87 ± 0.12 * 1.64 ± 0.01 *** 1.60 ± 0.01 **
Q5–Q1 diff 1 1.36 0.42 0.12 0.03
% diff 2 3.4 1.04 7.89 1.91
p trend <0.001 <0.001 <0.001 <0.001
Values are presented as means ± SEM. The p-trend was calculated using ANCOVA. 1 Q5–Q1 calculates the absolute difference between the
means of quintile (Q) 5 and Q1. 2 % difference calculates the percentage difference between the means of Q5 and Q1. * p < 0.05; ** p < 0.01;
*** p < 0.001 versus quintile 1, according to ANCOVA. FFM = fat-free mass. FFM and FFMBMI—adjusted model includes age, total energy,
protein intake as a percentage of total energy, smoking status, physical activity, corticosteroid use, menopausal status, HRT use, statins use,
social class and fat mass (FFM only).
3.5. Associations between Plasma Vitamin E Concentrations and Indices of SMM
In general, similar linear trends were found for both men and women, with those
across quintiles of α- and γ-tocopherol tending to be in the same direction, and the trend
for the ratio of α-tocopherol: γ-tocopherol was in the opposite direction (Table 4). Linear
trends in both men and women were most apparent across quintiles of plasma γ-tocopherol.
In adjusted plasma model analyses, there was a significant positive trend across both α-
and γ-tocopherol quintiles for FFM in men (p < 0.001) and women (p < 0.01). However, for
FFM, a significant negative trend was found across quintiles of the ratio of α-tocopherol:γ-
tocopherol in both men and women (p < 0.001). Whereas, across quintiles of the ratio
of α-tocopherol: γ-tocopherol, significant positive trends were found for FFM in both
men (p < 0.001) and women (p < 0.01), and significant negative trends for FFMBMI in
both men and women (p < 0.001). In the adjusted model for FFM, significant differences
were found between quintile 1 and quintiles 4 and 5 of plasma γ-tocopherol in women
(p < 0.01 and <0.05, respectively), whereas in men, significant differences were found
between quintile 1 and quintiles 2 (p < 0.01), 4 (p < 0.05) and 5 (p < 0.01) of the ratio
of α-tocopherol:γ-tocopherol. In the adjusted model for FFMBMI, significant differences
were found between Q1 and Q3 of plasma α-tocopherol in women (p < 0.05). Regarding
plasma γ-tocopherol, significant differences were found between Q1 and Q5 of plasma in
men (p < 0.01) and between Q1 and Q4 (p < 0.05) and 5 (p < 0.01) in women. In women,
significant differences were found between Q1 and Q4 (p < 0.01) and Q5 (p < 0.05) of the
ratio of α-tocopherol:γ-tocopherol.
3.6. Associations between Dietary Vitamin E Intakes and Bone Density Status
Mean calcaneal BUA values, stratified by sex and quintiles of dietary vitamin E, are
shown in Table 5, for unadjusted data and the fully adjusted model. Significant positive
associations across quintiles of dietary vitamin E intake were evident in both men and
women, after adjustments for covariates (p-trend < 0.001 in both men and women). In
the fully adjusted model, a significant difference was identified in men, for Q3 versus
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Q1 (+1.8%; p < 0.05). Further adjustment for the amount of vitamin E derived from
supplements did not modify the associations.
Table 4. Multivariate adjusted SMM indices for EPIC-Norfolk participants, stratified by sex and quintiles of plasma
α-tocopherol, plasma γ-tocopherol and α-tocopherol:γ-tocopherol ratio, adjusted for blood cholesterol measurement.
Men (n = 2232) Plasma α-Tocopherol, Adjustedfor Cholesterol (µmol/mmol) FFM FFMBMI
Quintile Mean ± SD Median Unadjusted Adjusted Unadjusted Adjusted
1 (n = 447) 3.17 ± 0.36 3.25 61.03 ± 0.27 61.13 ± 0.24 2.31 ± 0.01 2.31 ± 0.01
2 (n = 446) 3.80 ± 0.13 3.80 61.13 ± 0.25 61.14 ± 0.24 2.31 ± 0.01 2.31 ± 0.01
3 (n = 447) 4.23 ± 0.13 4.23 61.76 ± 0.28 61.72 ± 0.24 2.31 ± 0.01 2.32 ± 0.01
4 (n = 446) 4.71 ± 0.15 4.70 61.24 ± 0.28 61.31 ± 0.24 2.31 ± 0.01 2.31 ± 0.01
5 (n = 446) 5.86 ± 1.14 5.47 61.36 ± 0.29 61.23 ± 0.24 2.28 ± 0.01 * 2.28 ± 0.01
Q5-Q1 diff 1 0.33 0.10 −0.03 −0.03
% diff 2 0.54 0.16 −1.30 −1.30
p trend 0.413 <0.001 0.039 <0.001
Women (n = 2051) Plasma α-Tocopherol, Adjustedfor Cholesterol (µmol/mmol) FFM FFMBMI
Quintile Mean ± SD Median Unadjusted Adjusted Unadjusted Adjusted
1 (n = 411) 3.22 ± 0.39 3.32 40.41 ± 0.24 40.48 ± 0.23 1.58 ± 0.01 1.58 ± 0.01
2 (n = 410) 3.86 ± 0.13 3.87 40.19 ± 0.23 40.22 ± 0.23 1.56 ± 0.01 1.56 ± 0.01
3 (n = 410) 4.31 ± 0.13 4.30 40.34 ± 0.24 40.33 ± 0.23 1.54 ± 0.01 * 1.54 ± 0.01 *
4 (n = 410) 4.79 ± 0.16 4.79 40.75 ± 0.22 40.70 ± 0.23 1.57 ± 0.01 1.57 ± 0.01
5 (n = 410) 5.96 ± 1.03 5.61 40.58 ± 0.23 40.53 ± 0.23 1.55 ± 0.01 1.55 ± 0.01
Q5-Q1 diff 1 0.17 0.05 −0.03 −0.03
% diff 2 0.42 0.12 −1.90 −1.90
p trend 0.251 0.006 0.239 <0.001
Men (n = 2232) Plasma γ-Tocopherol, Adjustedfor Cholesterol (µmol/mmol) FFM FFMBMI
Quintile Mean ± SD Median Unadjusted Adjusted Unadjusted Adjusted
1 (n = 447) 0.15 ± 0.04 0.16 60.78 ± 0.28 60.94 ± 0.24 2.32 ± 0.01 2.32 ± 0.01
2 (n = 446) 0.22 ± 0.01 0.22 60.96 ± 0.26 61.29 ± 0.24 2.33 ± 0.01 2.32 ± 0.01
3 (n = 447) 0.28 ± 0.02 0.28 61.27 ± 0.28 61.24 ± 0.24 2.30 ± 0.01 2.30 ± 0.01
4 (n = 446) 0.34 ± 0.02 0.34 61.58 ± 0.27 * 61.53 ± 0.24 2.30 ± 0.01 2.31 ± 0.01
5 (n = 446) 0.51 ± 0.14 0.47 61.94 ± 0.27 ** 61.52 ± 0.24 2.27 ± 0.01 ** 2.27 ± 0.01 **
Q5-Q1 diff 1 1.16 0.58 −0.05 −0.05
% diff 2 1.91 0.95 −2.16 −2.16
p trend 0.0007 p < 0.0001 0.0009 p < 0.0001
Women (n = 2051) Plasma γ-Tocopherol, Adjustedfor Cholesterol (µmol/mmol) FFM FFMBMI
Quintile Mean ± SD Median Unadjusted Adjusted Unadjusted Adjusted
1 (n = 411) 0.14 ± 0.04 0.14 39.94 ± 0.22 39.93 ± 0.23 1.58 ± 0.01 1.58 ± 0.01
2 (n = 410) 0.21 ± 0.02 0.21 40.40 ± 0.24 40.39 ± 0.23 1.58 ± 0.01 1.58 ± 0.01
3 (n = 410) 0.26 ± 0.02 0.26 40.50 ± 0.23 40.52 ± 0.23 1.57 ± 0.01 1.57 ± 0.01
4 (n = 410) 0.33 ± 0.02 0.33 40.81 ± 0.23 ** 40.82 ± 0.23 ** 1.54 ± 0.01 * 1.54 ± 0.01 *
5 (n = 410) 0.48 ± 0.12 0.44 40.62 ± 0.23 * 40.61 ± 0.23 * 1.54 ± 0.01 ** 1.54 ± 0.01 **
Q5-Q1 diff 1 0.68 0.68 −0.04 −0.04
% diff2 1.70 1.70 −2.53 −2.53
p trend 0.0254 0.0017 0.0013 p < 0.0001
Men (n = 2232) Plasma α:γ-Tocopherol Ratio,Adjusted for Cholesterol FFM FFMBMI
Quintile Mean ± SD Median Unadjusted Adjusted Unadjusted Adjusted
1 (n = 447) 8.73 ± 1.48 8.99 62.22 ± 0.27 61.93 ± 0.24 2.29 ± 0.01 2.29 ± 0.01
2 (n = 446) 12.13 ± 0.82 12.15 61.04 ± 0.26 ** 60.97 ± 0.24 ** 2.29 ± 0.01 2.29 ± 0.01
3 (n = 447) 15.04 ± 0.90 14.96 61.37 ± 0.28 * 61.39 ± 0.24 2.32 ± 0.01 2.32 ± 0.01
4 (n = 446) 19.01 ± 1.46 18.87 61.11 ± 0.27 ** 61.24 ± 0.24 * 2.31 ± 0.01 2.31 ± 0.01
5 (n = 446) 34.97 ± 30.04 26.65 60.78 ± 0.28 *** 61.00 ± 0.24 ** 2.31 ± 0.01 2.31 ± 0.01
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Q5-Q1 diff 1 −1.44 −0.93 0.02 0.02
% diff 2 −2.31 −1.50 0.87 0.87
p trend 0.002 p < 0.001 0.109 p < 0.001
Women (n = 2051) Plasma α:γ-Tocopherol Ratio,Adjusted for Cholesterol FFM FFMBMI
Quintile Mean ± SD Median Unadjusted Adjusted Unadjusted Adjusted
1 (n = 411) 9.11 ± 1.60 9.44 40.51 ± 0.23 40.53 ± 0.23 1.54 ± 0.01 1.54 ± 0.01
2 (n = 410) 12.74 ± 0.90 12.78 40.87 ± 0.23 40.88 ± 0.23 1.55 ± 0.01 1.55 ± 0.01
3 (n = 410) 15.92 ± 1.04 15.83 40.37 ± 0.23 40.39 ± 0.23 1.55 ± 0.01 1.55 ± 0.01
4 (n = 410) 20.47 ± 1.74 20.31 40.30 ± 0.23 40.27 ± 0.23 1.59 ± 0.01 ** 1.59 ± 0.01 **
5 (n = 410) 44.84 ± 50.09 31.67 40.22 ± 0.22 40.20 ± 0.23 1.58 ± 0.01 * 1.58 ± 0.01 *
Q5-Q1 diff 1 −0.29 −0.33 0.04 0.04
% diff 2 −0.72 −0.81 2.60 2.60
p trend 0.133 0.003 0.003 p < 0.001
Values are presented as means ± SEM. The p-trend was calculated using ANCOVA. 1 Q5-Q1 calculates the absolute difference between the
means of quintile (Q) 5 and Q1. 2 % difference calculates the percentage difference between the means of Q5 and Q1. * p < 0.05; ** p < 0.01;
*** p < 0.001 versus quintile 1. FFM = fat-free mass. For the FFM model, ratios were adjusted for age, smoking status, physical activity,
corticosteroid and statin use, social class, fat mass, and menopausal status and HRT use in women. For the FFMBMI model, ratios were
adjusted for age, smoking status, physical activity, corticosteroid and statin use, social class, and menopausal status and HRT use in women.
Table 5. Associations between quintiles of dietary vitamin E and calcaneal BUA in men and women aged 42–82 years.
Men (n = 6443) Dietary α-Tocopherol EquivalentsIntake (mg/day) BUA
Quintile Mean ± SD Median Unadjusted Adjusted
1 (n = 1289) 6.45 ± 1.19 6.71 88.73 ± 0.50 89.03 ± 0.52
2 (n = 1289) 8.99 ± 0.53 9.01 90.06 ± 0.48 90.07 ± 0.49
3 (n = 1288) 10.93 ± 0.63 10.89 90.64 ± 0.48 ** 90.64 ± 0.48 *
4 (n = 1289) 13.46 ± 0.90 13.38 90.51 ± 0.49 * 90.39 ± 0.49
5 (n = 1288) 19.71 ± 4.63 18.30 90.34 ± 0.49 * 90.15 ± 0.52
Q5-Q1 diff 1 1.61 1.12
% diff 2 1.81 1.26
p trend 0.044 <0.001
Women (n = 8251)
Quintile Mean ± SD Median Unadjusted Adjusted
1 (n = 1651) 5.33 ± 0.98 5.54 70.85 ± 0.41 71.84 ± 0.39
2 (n = 1650) 7.38 ± 0.44 7.38 71.66 ± 0.40 72.16 ± 0.35
3 (n = 1650) 8.91 ± 0.46 8.93 71.13 ± 0.40 71.53 ± 0.35
4 (n = 1650) 10.72 ± 0.64 10.68 73.23 ± 0.41 *** 72.45 ± 0.35
5 (n = 1650) 15.13 ± 3.56 14.12 73.57 ± 0.41 *** 72.47 ± 0.38
Q5–Q1 diff 1 2.72 0.63
% diff 2 3.84 0.88
p trend <0.001 <0.001
Values are presented as means ± SEM. The p-trend was calculated using ANCOVA. 1 Q5–Q1 calculates the absolute difference between the
means of quintile (Q) 5 and Q1. 2 % difference calculates the percentage difference between the means of Q5 and Q1. * p < 0.05; ** p < 0.01;
*** p < 0.001 versus quintile 1, according to ANCOVA. BUA = broadband ultrasound attenuation. BUA—adjusted model includes age, BMI,
total energy, dietary calcium intake, dietary vitamin D intake, smoking status, physical activity, corticosteroid use, menopausal status, HRT
use, calcium and vitamin D supplement use and family history of osteoporosis.
3.7. Associations between Plasma Vitamin E Concentrations and Bone Density Status
Analysis of mean calcaneal bone density measures, stratified by sex and quintiles of
plasma vitamin E concentrations, is shown in Table 6, for both the unadjusted and fully
adjusted models. In both men and women, mean BUA measures tended to significantly
increase across quintiles of plasma α- and γ-tocopherol and decrease across quintiles of
the ratio of α-tocopherol:γ-tocopherol (p < 0.001). No significant differences were found
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between quintile 1 and any of the other quintiles in the adjusted models, in either men
or women.
3.8. Associations between Dietary Vitamin E Intakes and Fracture Risk
In the fully adjusted dietary model analyses, significant positive associations were
evident between quintiles of vitamin E intake and risk for total fractures and hip fractures
in both men and women (p < 0.001), but negative associations were found for wrist
fractures in women (p < 0.01) (Table 7). In men, both total fracture risk and wrist fracture
risk were significantly lower in Q2 versus Q1 (0.79; 95% CI 0.64, 0.98; p < 0.05 and 0.51;
95% CI 0.29, 0.90; p < 0.05, respectively). In women, hip fracture risk was significantly lower
in Q2 versus Q1 (0.81; 95% CI 0.66, 0.99; p < 0.05). The addition of supplement-derived
vitamin E intake to the fully adjusted models did not alter the associations.
3.9. Associations between Plasma Vitamin E Concentrations and Fracture Risk
In the fully adjusted plasma vitamin E analyses, significant linear trends were found
for risk of total and hip fractures and quintiles of plasma α-, γ-tocopherol and the ratio
of α-tocopherol:γ-tocopherol in men (p < 0.05) (Table 8). The risk for both total and hip
fracture decreased across quintiles of plasma α-tocopherol and the ratio of α-tocopherol:γ-
tocopherol, but increased across quintiles of γ-tocopherol for hip fracture risk and tended to
decrease for total fracture risk. In women, in the fully adjusted plasma vitamin E analyses,
significant linear trends were found for risk of total and hip fractures and quintiles of
plasma α-, γ-tocopherol and the ratio of α-tocopherol:γ-tocopherol (p < 0.05). The risk
for total and hip fractures tended to decrease across quintiles of plasma α-tocopherol and
the ratio of α-tocopherol:γ-tocopherol but increase across the quintiles of γ-tocopherol. In
men, spine fracture risk was significantly higher in Q3 versus Q1 (2.00; 95% CI 1.00, 4.00;
p < 0.05) in the fully adjusted ratio of α-tocopherol:γ-tocopherol model. Total fracture risk
in women was significantly higher in Q4 versus Q1 (1.29; 95% CI 1.01, 1.65; p < 0.05) in
the fully adjusted plasma γ-tocopherol model. However, hip fracture risk in women was
significantly lower in Q3 versus Q1 (0.61; 95% CI 0.41, 0.89; p < 0.05) in the fully adjusted
ratio of α-tocopherol:γ-tocopherol model. Wrist fracture risk in women was significantly
lower in Q5 versus Q1 (0.56; 95% CI 0.32, 0.98; p < 0.05) in the fully adjusted plasma
α-tocopherol model.
The associations of dietary intake and plasma concentrations of vitamin E with SMM,
BUA and fracture risk are summarised in Table 9.
Table 6. Multivariate adjusted calcaneal BUA for EPIC-Norfolk participants, stratified by sex and quintiles of plasma
α-tocopherol, plasma γ-tocopherol and α-tocopherol:γ-tocopherol ratio, adjusted for by blood cholesterol measurement.
Men (n = 2308) Plasma α-Tocopherol, Adjusted forCholesterol (µmol/mmol) BUA
Quintile Mean ± SD Median Unadjusted Adjusted
1 (n = 462) 3.17 ± 0.36 3.26 88.97 ± 0.82 89.11 ± 0.82
2 (n = 462) 3.80 ± 0.13 3.80 89.01 ± 0.81 88.87 ± 0.82
3 (n = 461) 4.24 ± 0.13 4.24 89.22 ± 0.83 89.01 ± 0.82
4 (n = 462) 4.72 ± 0.15 4.70 89.84 ± 0.83 89.84 ± 0.82
5 (n = 461) 5.90 ± 1.20 5.50 90.19 ± 0.84 90.38 ± 0.83
Q5–Q1 diff 1 1.22 1.27
% diff 2 1.37 1.42
p trend 0.209 <0.001
Women (n = 2149) Plasma α-Tocopherol, Adjusted forCholesterol (µmol/mmol) BUA
Quintile Mean ± SD Median Unadjusted Adjusted
1 (n = 430) 3.22 ± 0.41 3.33 68.74 ± 0.81 69.29 ± 0.66
2 (n = 430) 3.86 ± 0.13 3.87 69.22 ± 0.79 69.47 ± 0.66
3 (n = 430) 4.31 ± 0.13 4.30 69.38 ± 0.72 69.25 ± 0.66
4 (n = 430) 4.80 ± 0.16 4.80 70.86 ± 0.78 70.72 ± 0.66
5 (n = 429) 5.96 ± 1.02 5.63 70.95 ± 0.78 * 70.44 ± 0.67
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Q5–Q1 diff 1 2.21 1.15
% diff 2 3.22 1.66
p trend 0.015 <0.001
Men (n = 2308) Plasma γ-Tocopherol, Adjusted forCholesterol (µmol/mmol) BUA
Quintile Mean ± SD Median Unadjusted Adjusted
1 (n = 462) 0.15 ± 0.04 0.16 88.93 ± 0.79 88.68 ± 0.83
2 (n = 462) 0.22 ± 0.02 0.23 89.16 ± 0.86 89.09 ± 0.82
3 (n = 461) 0.28 ± 0.02 0.28 89.10 ± 0.84 88.94 ± 0.82
4 (n = 462) 0.35 ± 0.02 0.34 89.50 ± 0.82 89.80 ± 0.82
5 (n = 461) 0.51 ± 0.14 0.47 90.54 ± 0.82 90.69 ± 0.82
Q5–Q1 diff 1 1.61 2.01
% diff 2 1.81 2.27
p trend 0.141 p < 0.001
Women (n = 2149) Plasma γ-Tocopherol, Adjusted forCholesterol (µmol/mmol) BUA
Quintile Mean ± SD Median Unadjusted Adjusted
1 (n = 430) 0.14 ± 0.04 0.14 69.45 ± 0.79 68.46 ± 0.67
2 (n = 430) 0.21 ± 0.02 0.21 69.22 ± 0.78 68.86 ± 0.66
3 (n = 430) 0.27 ± 0.02 0.26 68.93 ± 0.78 69.03 ± 0.66
4 (n = 430) 0.33 ± 0.02 0.33 70.34 ± 0.76 70.69 ± 0.66
5 (n = 429) 0.49 ± 0.13 0.44 71.21 ± 0.78 72.12 ± 0.66
Q5–Q1 diff 1 1.76 3.66
% diff 2 2.53 5.35
p trend 0.046 p < 0.001
Men (n = 2308) Plasma α:γ-Tocopherol Ratio,Adjusted for Cholesterol BUA
Quintile Mean ± SD Median Unadjusted Adjusted
1 (n = 462) 8.73 ± 1.46 9.00 89.44 ± 0.82 89.67 ± 0.83
2 (n = 462) 12.10 ± 0.82 10.70 89.56 ± 0.81 89.67 ± 0.82
3 (n = 461) 14.97 ± 0.88 13.51 89.78 ± 0.85 89.76 ± 0.82
4 (n = 462) 18.91 ± 1.45 16.59 89.51 ± 0.82 89.31 ± 0.82
5 (n = 461) 35.15 ± 30.64 21.69 88.95 ± 0.82 88.79 ± 0.83
Q5–Q1 diff 1 −0.49 −0.88
% diff 2 −0.55 −0.98
p trend 0.602 p < 0.001
Women (n = 2149) Plasma α:γ-Tocopherol Ratio,Adjusted for Cholesterol BUA
Quintile Mean ± SD Median Unadjusted Adjusted
1 (n = 430) 9.06 ± 1.62 9.42 70.31 ± 0.79 71.02 ± 0.66
2 (n = 430) 12.67 ± 0.90 12.75 70.03 ± 0.74 70.97 ± 0.66
3 (n = 430) 15.81 ± 1.02 15.75 69.32 ± 0.78 69.31 ± 0.66
4 (n = 430) 20.35 ± 1.76 20.13 69.68 ± 0.80 69.10 ± 0.66
5 (n = 429) 44.22 ± 57.93 31.23 69.81 ± 0.79 68.74 ± 0.68
Q5–Q1 diff 1 −0.50 −2.28
% diff 2 −0.71 −3.21
p trend 0.731 p < 0.001
Values are presented as means ± SEM. The p-trend was calculated using ANCOVA. BUA = broadband ultrasound attenuation. 1 Q5–Q1
calculates the absolute difference between the means of quintile (Q) 5 and Q1. 2 % difference calculates the percentage difference between
the means of Q5 and Q1. * p < 0.05 versus quintile 1. Ratios were adjusted for age, BMI, smoking status, physical activity, family history of
osteoporosis, corticosteroid use, dietary calcium intake, dietary vitamin D intake, calcium and vitamin D supplement use, and menopausal
status and HRT use in women.
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Table 7. Risk of total, hip, spine and wrist fractures in EPIC-Norfolk participants, stratified by sex and quintiles of dietary vitamin E intake (n = 25,223).
Men (n = 11,427) Total Fractures Hip Fracture Spine Fracture Wrist Fracture






Q1 2286 5.95 1.25 6.23 188/2286 1.00 Ref. 80/2286 1.00 Ref. 49/2286 1.00 Ref. 33/2286 1.00 Ref.
Q2 2285 8.65 0.59 8.67 161/2285 0.79 * 0.64 0.98 74/2285 0.89 0.64 1.23 47/2285 0.94 0.62 1.41 20/2285 0.51 * 0.29 0.90
Q3 2286 10.65 0.61 10.62 176/2286 0.94 0.76 1.17 62/2286 0.86 0.61 1.22 49/2286 1.10 0.73 1.67 32/2286 0.80 0.48 1.34
Q4 2285 13.22 0.92 13.11 158/2285 0.86 0.68 1.08 72/2285 1.08 0.76 1.53 33/2285 0.77 0.48 1.24 38/2285 0.88 0.53 1.47
Q5 2285 19.71 4.92 18.22 194/2285 1.06 0.84 1.34 68/2285 1.05 0.73 1.52 45/2285 1.09 0.68 1.75 32/2285 0.68 0.38 1.19
877/11,427 356/11,427 223/11,427 155/11,427
p trend p < 0.001 p < 0.001 0.21 0.11
Women (n = 13,796) Total Fractures Hip Fracture Spine Fracture Wrist Fracture






Q1 2760 5.04 1.03 5.25 479/2760 1.00 Ref. 228/2760 1.00 Ref. 89/2760 1.00 Ref. 108/2760 1.00 Ref.
Q2 2759 7.14 0.45 7.15 438/2759 0.93 0.81 1.06 177/2759 0.81 * 0.66 0.99 80/2759 0.94 0.68 1.28 104/2759 1.05 0.80 1.39
Q3 2759 8.70 0.46 8.68 427/2759 0.93 0.81 1.07 212/2759 1.04 0.85 1.27 63/2759 0.77 0.55 1.09 102/2759 1.08 0.81 1.44
Q4 2759 10.55 0.66 10.50 377/2759 0.88 0.76 1.02 175/2759 0.93 0.75 1.16 67/2759 0.90 0.63 1.28 104/2759 1.20 0.89 1.63
Q5 2759 15.01 3.48 14.01 371/2759 0.90 0.77 1.06 179/2759 1.02 0.81 1.29 58/2759 0.82 0.55 1.21 86/2759 1.07 0.77 1.50
2092/13,796 971/13,796 357/13,796 504/13,796
p trend p < 0.001 p < 0.001 0.09 p < 0.01
* p < 0.05 versus quintile 1. Ratios were adjusted for age, BMI, smoking status, physical activity, family history of osteoporosis, calcium intake, vitamin D intake, energy intake, calcium- and vitamin D-containing
supplement use, corticosteroid use, and menopausal status and HRT use in women.
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Table 8. Risk of total, hip, spine and wrist fractures in EPIC-Norfolk participants, stratified by sex and quintiles of plasma α-tocopherol, plasma γ-tocopherol and the ratio of α:γ, adjusted
for cholesterol.
Men (n = 3727) Total Fractures Hip Fractures Spine Fractures Wrist Fractures
Mean SD Median Incidence HR 95% CI Incidence HR 95% CI Incidence HR 95% CI IncidenceHR 95% CI
Plasma α-tocopherol, adjusted for
cholesterol (µmol/mmol)
3.13 0.39 3.23 67/746 1.00 Ref. 31/746 1.00 Ref. 20/746 1.00 Ref. 4/746 1.00 Ref.
3.79 0.13 3.79 52/745 0.79 0.54 1.13 20/745 0.62 0.35 1.11 16/745 0.84 0.43 1.62 10/745 2.41 0.75 7.72
4.22 0.13 4.22 61/746 0.90 0.63 1.27 25/746 0.82 0.48 1.39 18/746 0.87 0.46 1.65 10/746 2.29 0.71 7.35
4.70 0.16 4.69 65/745 0.88 0.63 1.24 27/745 0.78 0.47 1.32 17/745 0.78 0.41 1.50 8/745 1.76 0.52 5.87
5.88 1.12 5.51 63/745 0.86 0.61 1.23 26/745 0.79 0.46 1.35 18/745 0.81 0.42 1.56 8/745 1.79 0.53 6.05
p trend 0.028 0.007 0.460 0.787
Plasma γ-tocopherol, adjusted for
cholesterol (µmol/mmol)
0.15 0.04 0.16 60/746 1.00 Ref. 23/746 1.00 Ref. 20/746 1.00 Ref. 7/746 1.00 Ref.
0.23 0.02 0.23 52/745 0.85 0.58 1.24 24/745 1.03 0.58 1.85 13/745 0.63 0.31 1.28 9/745 1.25 0.46 3.39
0.28 0.02 0.28 61/746 0.97 0.68 1.40 27/746 1.09 0.62 1.94 21/746 1.00 0.54 1.85 6/746 0.83 0.28 2.53
0.35 0.02 0.35 75/745 1.21 0.85 1.71 30/745 1.22 0.69 2.14 21/745 0.98 0.53 1.83 9/745 1.28 0.47 3.49
0.52 0.13 0.48 60/745 0.94 0.65 1.37 25/745 1.04 0.57 1.86 14/745 0.60 0.29 1.22 9/745 1.31 0.47 3.63
p trend 0.029 0.008 0.425 0.776
Plasma α-tocopherol:γ-tocopherol
ratio, adjusted for cholesterol
8.56 1.43 8.87 60/746 1.00 Ref. 28/746 1.00 Ref. 13/746 1.00 Ref. 7/746 1.00 Ref.
11.90 0.77 11.93 64/745 1.00 0.70 1.42 31/745 0.94 0.56 1.57 19/745 1.53 0.74 3.17 5/745 0.67 0.21 2.12
14.71 0.87 14.66 76/746 1.18 0.84 1.66 28/746 0.85 0.50 1.45 25/746 2.00* 1.00 4.00 11/746 1.42 0.55 3.68
18.53 1.39 18.40 50/745 0.86 0.59 1.26 15/745 0.55 0.29 1.04 19/745 1.65 0.79 3.43 8/745 1.13 0.40 3.16
34.08 27.74 25.88 58/745 0.96 0.66 1.40 27/745 0.96 0.55 1.68 13/745 1.09 0.49 2.44 9/745 1.24 0.44 3.45
p trend 0.027 0.007 0.490 0.765
Women (n = 3564) Total Fractures Hip Fractures Spine Fracture Wrist Fracture
Mean SD Median Incidence HR 95% CI Incidence HR 95% CI Incidence HR 95% CI IncidenceHR 95% CI
Plasma α-tocopherol, adjusted for
cholesterol (µmol/mmol)
3.20 0.42 3.32 138/713 1.00 Ref. 66/713 1.00 Ref. 24/713 1.00 Ref. 37/713 1.00 Ref.
3.86 0.13 3.86 124/713 0.87 0.68 1.11 66/713 0.99 0.70 1.39 25/713 1.05 0.60 1.84 26/713 0.67 0.40 1.12
4.30 0.12 4.29 125/713 0.98 0.77 1.25 62/713 1.08 0.76 1.52 23/713 1.04 0.58 1.84 34/713 0.98 0.61 1.56
4.78 0.17 4.77 132/713 1.03 0.81 1.31 56/713 0.93 0.65 1.33 27/713 1.20 0.69 2.10 36/713 1.04 0.65 1.65
5.97 1.04 5.61 124/712 0.94 0.73 1.20 63/712 1.04 0.73 1.49 25/712 1.03 0.57 1.85 19/712 0.56 * 0.32 0.98
p trend 0.010 0.013 0.665 0.075
Plasma γ-tocopherol, adjusted for
cholesterol (µmol/mmol)
0.14 0.04 0.15 125/713 1.00 Ref. 62/713 1.00 Ref. 26/713 1.00 Ref. 32/713 1.00 Ref.
0.21 0.02 0.21 132/713 1.11 0.87 1.42 60/713 1.01 0.71 1.45 23/713 0.91 0.52 1.62 31/713 1.04 0.63 1.71
0.27 0.02 0.27 125/713 1.09 0.84 1.40 57/713 0.97 0.67 1.41 29/713 1.13 0.65 1.96 33/713 1.17 0.71 1.92
0.33 0.02 0.33 143/713 1.29 * 1.01 1.65 76/713 1.36 0.96 1.93 28/713 1.20 0.69 2.09 30/713 1.04 0.62 1.75
0.50 0.13 0.46 118/712 1.07 0.82 1.39 58/712 1.05 0.72 1.52 18/712 0.75 0.40 1.40 26/712 1.00 0.58 1.70
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p trend 0.009 0.011 0.486 0.108
Plasma α-tocopherol:γ-tocopherol
ratio, adjusted for cholesterol
8.91 1.66 9.30 131/713 1.00 Ref. 69/713 1.00 Ref. 23/713 1.00 Ref. 29/713 1.00 Ref.
12.53 0.89 12.58 130/713 0.96 0.76 1.23 70/713 1.01 0.72 1.41 23/713 1.02 0.57 1.83 23/713 0.73 0.42 1.28
15.64 0.99 15.56 123/713 0.90 0.70 1.15 43/713 0.61 * 0.41 0.89 29/713 1.30 0.75 2.26 42/713 1.40 0.87 2.26
20.06 1.70 19.87 138/713 0.98 0.77 1.25 71/713 0.97 0.69 1.36 25/713 1.02 0.57 1.82 31/713 0.93 0.56 1.56
42.51 50.07 30.12 121/712 0.84 0.65 1.10 60/712 0.83 0.58 1.19 24/712 0.97 0.53 1.79 27/712 0.84 0.48 1.44
p trend 0.007 0.011 0.507 0.099
* p < 0.05 versus quintile 1. Ratios were adjusted for age, BMI, smoking status, physical activity, family history of osteoporosis, calcium intake, vitamin D intake, calcium- and vitamin D-containing supplement
use, corticosteroid use and menopausal status and HRT use in women.


























FFM Men positive *** 1.03 positive *** 0.16 positive *** 0.95 negative *** −1.50
Women positive *** 1.04 positive ** 0.12 positive ** 1.70 negative ** −0.81
FFMBMI Men positive *** 1.74 negative *** −1.30 negative *** −2.16 positive *** 0.87
Women positive *** 1.91 negative *** −1.90 negative *** −2.53 positive *** 2.60
BUA Men positive *** 1.26 positive *** 1.42 positive *** 2.27 negative *** −0.98
Women positive *** 0.88 positive *** 1.66 positive *** 5.35 negative *** −3.21
Total fracture risk 2 Men positive *** positive * positive * positive *
Women positive *** positive * negative ** positive **
Hip fracture risk 2 Men positive *** positive ** negative ** positive **
Women positive *** positive * negative * positive *
Spine fracture risk 2 Men N.S. N.S. N.S. N.S.
Women N.S. N.S. N.S. N.S.
Wrist fracture risk 2 Men N.S. N.S. N.S. N.S.
Women negative ** N.S. N.S. N.S.
FFM = fat-free mass; BUA = broadband ultrasound attenuation. 1 (Q5 mean − Q1 mean/Q1 mean) × 100. 2 Positive associations with fracture risk indicate lower risk with higher tocopherol, while negative
associations indicate higher risk. * p < 0.05; ** p < 0.01; *** p < 0.001.
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4. Discussion
To our knowledge, this is the first study using data from a large population cohort of
middle- and older-aged men and women in the UK to assess the associations between both
dietary vitamin E intake and plasma vitamin E concentrations and indices of SMM, bone
density status and fracture risk. Our results show significant positive associations between
both dietary vitamin E intake and plasma concentrations of both serum cholesterol-adjusted
α- and γ-tocopherol and FFM and BUA, and generally significant positive associations for
fracture risk. The associations found with vitamin E for bone density status and fracture
risk are independent of vitamin D and calcium intake, which are both known to be relevant
for bone health. The results from this study indicate protection for musculoskeletal health
with higher intakes and blood concentrations of vitamin E.
In the EPIC-Norfolk study, the mean daily dietary intakes of vitamin E in 11,535 men
and 13,972 women, assessed using a 7dDD and expressed in milligrams of α-tocopherol
equivalents, were 11.62 (SD 5.24) and 9.27 (SD 3.78) mg [48] which is very similar to the
mean daily intakes in the cohorts in these analyses. These dietary intakes are in agreement
with those from other European countries [62,63]. Although in relation to the AIs defined
by EFSA [59], only 31% of men and 26% of women met the AIs.
Most studies conducted in the US reported higher average plasma γ-tocopherol levels
as compared to studies conducted in Europe [32]. This is likely explained by the fact
that γ-tocopherol is the major form (approximately 70%) of vitamin E in the US diet [31].
Therefore, this study focuses on European comparisons. The mean plasma α- and γ-
tocopherol concentrations in our study cohorts are similar to those found in a healthy Irish
adult population [63] and in the UK National Diet and Nutrition Survey (NDNS) [64].
More than 99% of both men and women in our study cohorts had higher plasma tocopherol
concentrations or tocopherol:cholesterol ratios than the minimum satisfactory values [58].
Our study found a number of weak but significant correlations between the dietary
intake of α-tocopherol equivalents and plasma concentrations of α-tocopherol, which has
also been observed in a small German study [65] (n = 92; r = 0.14) but no associations
have been found in a number of other European studies [66–68]. However, Kardinaal et al.
found a significant age- and sex-adjusted correlation (r = 0.24, p < 0.05) for α-tocopherol
between intake and adipose tissue levels in a small study of healthy adults [66], whereas
no correlation was found between the adipose tissue level of alpha-tocopherol and dietary
intake by Andersen et al. [67].
Significant positive trends in FFM and FFMBMI were evident across increasing quintiles
of dietary vitamin E intake for both sexes, after adjusting for important covariates. Similar
linear trends were generally apparent in both men and women for plasma vitamin E
concentrations, with those across quintiles of α- and γ-tocopherol tending to be in the
same direction (positive for FFM but negative for FFMBMI), and the trend for the ratio
of α-tocopherol:γ-tocopherol in the opposite direction (negative for FFM but positive
for FFMBMI). These seemingly contradictory findings are not surprising as the increase
in the ratio across quintiles is due to decreasing plasma α- but increasing γ-tocopherol
concentrations. Whereas across increasing quintiles of plasma α-tocopherol, γ-tocopherol
also increased, and across increasing quintiles of γ-tocopherol, plasma concentrations of
α-tocopherol tended to decrease slightly. To date, most studies that have investigated
the potential role of vitamin E in muscle health have focused on muscle function and
strength rather than muscle mass and found that higher dietary vitamin E intakes [22,26]
and plasma vitamin E concentrations were associated with higher strength measures and
physical performance tests or lower levels of frailty [21,23,24,69–71]. Findings from our
study support the importance of vitamin E to skeletal muscle health.
Significant trends were apparent for BUA across quintiles of dietary vitamin E in-
take and plasma concentrations in both men and women, with BUA tending to increase
across quintiles of dietary vitamin E intake and plasma α- and γ-tocopherol but decrease
across quintiles of the ratio of α-tocopherol:γ-tocopherol (p < 0.001). Significant positive
associations were evident for dietary vitamin E intake and risk for total and hip fractures
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in both men and women (p < 0.001), but a significant negative association was found for
wrist fracture risk in women (p < 0.01), where the greatest number of fractures was found
in Q1, and the lowest in Q5; it is possible that this association may be artefactual. In
plasma vitamin E analyses, significant linear trends were found for total fracture risk in
men (p < 0.05) with the risk of total fractures generally decreasing across the quintiles in
all 3 models. Significant linear associations were also found for hip fracture risk in men
(p < 0.01), with the risk of hip fracture decreasing across quintiles of plasma α-tocopherol
and the ratio of α-tocopherol:γ-tocopherol but increasing across quintiles of γ-tocopherol.
In women, significant linear trends were found for risk of total and hip fractures and
plasma vitamin E (p < 0.05), with the risk of fractures generally decreasing across quintiles
of plasma α-tocopherol and the ratio of α-tocopherol:γ-tocopherol but increasing across
quintiles of γ-tocopherol.
In the Aberdeen Prospective Osteoporosis Screening Study (APOSS) cohort, no bi-
ologically meaningful changes in BMD or bone resorption and formation markers with
dietary intakes or serum concentrations of tocopherols or the α/γ ratio were found in
perimenopausal and postmenopausal women [72], although dietary vitamin E intake
was negatively associated with femoral neck BMD in early postmenopausal women in
Scotland [73]. A recent study of nutrient intake and BMD in postmenopausal women
found that a high intake of vitamin E had a negative effect on BMD [74]. Low serum
concentrations of α- tocopherol have been associated with an increased risk of hip fracture
in elderly men and women [75] and an increased osteoporosis risk in postmenopausal
women [27]. Both low intakes and serum concentrations of α-tocopherol were associated
with an increased rate of fracture in elderly Swedish men and women [28]. There are a
number of plausible explanations for the heterogeneity of the conclusions of the aforemen-
tioned epidemiological studies—the use of different covariates in the multivariable models,
inconsistent measurement validity of biomarkers and the application of various exclusion
criteria regarding the study sample—although most concur with our findings. Whether or
not these study findings have any biological significance is unclear.
A recent review on the beneficial and detrimental effects of oxidative stress on human
health concluded that α- and γ-tocopherol forms of vitamin E exert a differential set of
biological effects, which cannot always be regarded as positive to human health [76]. Recent
data have also suggested that plasma α-tocopherol concentrations are more dependent
on mechanisms that control circulating lipids rather than those related to its absorption
and initial incorporation into plasma [77]; α-tocopherol was found to remain in circulation
longer in participants with higher serum lipids, but its absorption was not dependent on
the plasma lipid status.
In contrast to a high affinity to α-tocopherol (100%), α-tocopherol transfer protein
(α-TTP) has a much lower affinity towards other vitamin E forms; 50%, 10–30%, and
1% affinity to β-tocopherol, γ-tocopherol, and δ-tocopherol, respectively [78], and plays
an important role in the maintenance of high concentrations of α-tocopherol in plasma
and some tissues [79,80]. A reduction in plasma γ-tocopherol during enhanced intake
of α-tocopherol, such as through supplemental intake, can be explained by the more
rapid metabolism of γ-tocopherol occurring when α-tocopherol intake is increased [81].
Chylomicron-associated tissue uptake of vitamin E may contribute to the accumulation of
non-α-tocopherol forms of vitamin E such as γ-tocopherol in human skin, adipose tissue,
and muscle, where unexpectedly high concentrations of γ-tocopherol were observed, in
contrast to its low levels in the plasma [82]. Many unique properties have been attributed
to γ-tocopherol and its metabolites [83], which exhibit sometimes enhanced or different
activities of α-tocopherol such as natriuretic, anti-inflammatory, antitumoural activities, as
summarised in a recent review [84]. The ratio of α-tocopherol:γ-tocopherol is suggested
as a correction method as it would respond to even a small increase in α-tocopherol from
supplementation that may not be clearly evident in plasma α-tocopherol concentrations [85].
Findings from the analyses in this study have shown that adjustment for the amount of
vitamin E from supplements did not affect the associations.
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The interactions between these two tocopherols are complex within the body and it
must also be remembered that the bioavailability of vitamin E is influenced by a number of
factors, including other nutrients, genetics, absorption, transport and metabolism [86]. With
regard to other nutrients and food intake, data from the NDNS found that α-tocopherol
correlated directly with “healthy” nutrient choices (intrinsic sugars, dietary fibre, and
vitamins) and inversely with “unhealthy” choices (extrinsic sugars and monounsaturated
fats—i.e., avoidance of polyunsaturated fat), whilst γ-tocopherol and the γ-tocopherol:α-
tocopherol ratio related inversely with “healthy” choices, with the authors concluding
that the γ-tocopherol:α-tocopherol ratio may reveal poor dietary choices, which may
subsequently lead to health issues in later life [87].
A number of possible mechanisms have been suggested illustrating how vitamin
E may slow down the aging of skeletal muscle: (1) by improving antioxidant capacity,
thereby reducing oxidative stress and inflammation; (2) improving membrane repair
and increasing survival of damaged skeletal muscle by reducing oxidized phospholipid
formation; (3) improving mitochondrial efficiency; (4) decreasing glycogen usage in skeletal
muscle, while increasing fat metabolism; (5) enhancing muscle regeneration capacity;
(6) stabilize insulin structure and improve insulin sensitivity of skeletal muscle [35]. It is
thought that reduction in oxidative stress may also be a plausible mechanism whereby
vitamin E protects bone, although the reported opposing inflammatory functions of α-
and γ-tocopherol may result in an increase in bone resorption without affecting bone
formation [36]. However, further research is needed to investigate the potential effects of
other tocopherols and tocotrienols on sarcopenic and osteoporotic risk factors.
The strengths of our study include a large population size of middle-aged and elderly
men and women, from whom we had measures of dietary and supplemental intake, ob-
tained from 7dDDs, in addition to plasma concentrations of vitamin E (α- and γ-tocopherol),
in order to study the potential associations of vitamin E with indices of SMM, BUA and frac-
ture risk (over 18.5 years of follow-up). Limitations of our study include the observational
and cross-sectional study design regarding SMM and BUA measurements, precluding
us from inferring causation, and the use of self-reported measures for dietary intake and
physical activity. However, the prospective nature of our study of fracture risk and long
follow-up for end points of 18.5 years are advantages. In addition, the 7dDDs developed
for use in the EPIC-Norfolk study have previously been validated and are expected to
produce a more precise measure of dietary intake than 24 h diet recalls or food frequency
questionnaires [48]. Plasma vitamin E concentrations were only available for a small subset
of the cohort, which may have reduced the power of our analyses. Nevertheless, the
availability of plasma concentrations, which are not subject to nonrandom biases that
can affect questionnaire-based measurements, is a strength of our study, although these
concentrations may be affected by various physiological effects. SMMs were calculated
from weight, height and bioelectrical impedance measurements, and not from potentially
more accurate and precise methods, such as DEXA, computer tomography or magnetic
resonance imaging; however, this method has comparable acceptability in population
studies [88]. The dietary and lifestyle data, including the consumption of corticosteroids,
HRT and dietary supplements, used in the longitudinal analyses were collected at 1HE and
we were unable to account for any changes in exposures which may have occurred over
time and potentially affected the associations.
5. Conclusions
Our research has found significant positive associations between greater intakes of
dietary vitamin E and SMM indices, bone density status and total and hip fracture risk
in both middle-aged and elderly men and women, with the scale of effects ranging from
0.88% to 1.91% (p < 0.001). Associations found with circulating plasma α- and γ-tocopherol
generally agreed with the dietary data. These findings suggest that dietary vitamin E
intake may play a role in musculoskeletal health and provides evidence of the benefits of
higher vitamin E intakes, similar to the AIs of α-tocopherol for adults of 13 mg/day for
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men and 11 mg/d for women, as recommended by EFSA. These intakes can be achieved
by eating a varied and balanced diet, including the consumption of foods rich in vitamin
E, such as oily seeds and their derivatives, nuts and cereals rich in vitamin E, including
fortified breakfast cereals. Where it is not possible to obtain adequate intakes through
the diet, vitamin E supplements should be consumed, especially in those at sarcopenic or
osteoporotic risk. Further investigation is required to understand the relationships with
plasma concentrations and musculoskeletal health.
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